BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31623615)

  • 1. Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy.
    Liu C; Jing W; An N; Li A; Yan W; Zhu H; Yu J
    J Transl Med; 2019 Oct; 17(1):344. PubMed ID: 31623615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.
    Karagöz B; Bilgi O; Gümüs M; Erikçi AA; Sayan O; Türken O; Kandemir EG; Oztürk A; Yaylaci M
    Med Oncol; 2010 Mar; 27(1):29-33. PubMed ID: 19148592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
    Liu C; Hu Q; Hu K; Su H; Shi F; Kong L; Zhu H; Yu J
    J Transl Med; 2019 Apr; 17(1):120. PubMed ID: 30971280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
    Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
    Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
    Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
    Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating CD8
    Song Q; Ren J; Zhou X; Wang X; Song G; Hobeika A; Yuan Y; Lyerly HK
    Cytotherapy; 2018 Jan; 20(1):126-133. PubMed ID: 28988693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer.
    Kinoshita T; Muramatsu R; Fujita T; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Kudo-Saito C; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H; Kawakami Y
    Ann Oncol; 2016 Nov; 27(11):2117-2123. PubMed ID: 27502728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.
    Boulle G; Velut Y; Mansuet-Lupo A; Gibault L; Blons H; Fournel L; Boni A; Cremer I; Wislez M; Duchatelle V; Trédaniel J; Hammond SA; Herbst R; Alifano M; Giraud P; Damotte D
    Eur J Cancer; 2020 Aug; 135():221-229. PubMed ID: 32610210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD3+ CD4+ and CD3+ CD8+ lymphocyte subgroups and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer.
    Yu DP; Han Y; Zhao QY; Liu ZD
    Asian Pac J Cancer Prev; 2014; 15(6):2685-8. PubMed ID: 24761885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
    O'Callaghan DS; Rexhepaj E; Gately K; Coate L; Delaney D; O'Donnell DM; Kay E; O'Connell F; Gallagher WM; O'Byrne KJ
    Eur Respir J; 2015 Dec; 46(6):1762-72. PubMed ID: 26541534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy.
    Liu C; Wu S; Meng X; Liu G; Chen D; Cong Y; Shen G; Sun B; Wang W; Wang Q; Gao H; Liu X
    Oncotarget; 2017 Jun; 8(26):43427-43438. PubMed ID: 28624781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
    Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Giatromanolaki A; Anestopoulos I; Panayiotidis MI; Mitrakas A; Pappa A; Koukourakis MI
    Anticancer Res; 2021 Aug; 41(8):3989-3995. PubMed ID: 34281863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 20. CD28/PD1 co-expression: dual impact on CD8
    Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
    J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.